Citizens Reiterates Buy on Mirum Pharma, Sees 42% Upside
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
mirum-pharmaceuticalsbiotech-stocks
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Citizens JMP Securities reaffirmed its Buy rating on Mirum Pharmaceuticals, Inc. (MIRM) on June 1, 2026. The firm maintained a $67 price target, representing a 42% premium to the stock's closing price of $47.20 on May 31. The analysts cited confidence in the biotech company's late-stage clinical pipeline, specifically targeting cholestatic liver diseases, as the basis for the reiteration.
The rating comes at a critical juncture for Mirum's two lead drug candidates. Volixibat is in Phase 3 trials for primary sclerosing cholangitis (PSC), with topline data expected in Q4 2026. Livmarli, already approved for Alagille syndrome, is undergoing a Phase 3 study for progressive familial intrahepatic cholestasis (PFIC), with results anticipated in early 2027. The last significant catalyst for Mirum was the FDA approval of Livmarli for Alagille syndrome in September 2021, which propelled the stock to a then-all-time high above $55. The current macro backdrop of elevated interest rates has pressured speculative biotech valuations, making positive clinical data essential for sustaining investor interest and funding further development. The trigger for Citizens' reaffirmation is the proximity of these two high-impact binary events within the next 12-18 months.
Mirum's market capitalization stands at approximately $2.1 billion based on 44.5 million shares outstanding. The stock is down 18% year-to-date, significantly underperforming the SPDR S&P Biotech ETF (XBI), which is up 5% over the same period. This underperformance highlights the market's risk-off stance ahead of clinical data readouts. The $67 price target implies an enterprise value-to-revenue multiple expansion from the current 8x to roughly 12x, based on consensus 2027 sales estimates of $550 million. Analysts project Livmarli sales could reach $400 million annually by 2028 if the PFIC label expansion is successful. Institutional ownership remains high at 78%, but short interest has crept up to 12% of the float, reflecting a divergence of opinion on trial outcomes.
| Metric | Value | Comparison/Note |
|---|---|---|
| Current Price | $47.20 | May 31, 2026 close |
| Price Target | $67.00 | Citizens JMP, 42% upside |
| Market Cap | ~$2.1B | Based on 44.5M shares |
| YTD Performance | -18% | XBI ETF YTD: +5% |
Positive data for either Volixibat or Livmarli's new indication would validate Mirum's platform and likely trigger a re-rating of the entire cholestatic liver disease segment. Competitors like Albireo Pharma, now part of Ipsen, could face increased commercial pressure on its drug Bylvay. Success would also benefit contract research organizations like IQVIA and PPD that manage these large, global trials. The primary counter-argument centers on clinical risk; Phase 3 failure rates in hepatology are near 50%, and a miss for either program could erase over half of Mirum's market value. Positioning data shows hedge funds are building paired trades, going long Mirum while shorting smaller, earlier-stage liver disease developers like CymaBay Therapeutics to hedge broader sector risk. Flow analysis indicates options activity is skewed towards calls for the January 2027 expiry, aligning with the expected PFIC data catalyst.
The next 18 months present two definitive catalysts. The Volixibat VISTAS trial top-line results for PSC are expected in Q4 2026. Following that, the MARCH-PFIC Phase 3 trial data for Livmarli is anticipated in Q1 2027. Investors should monitor enrollment completion for the MARCH-PFIC study, expected by Q3 2026, as a de-risking event. From a technical perspective, key support for MIRM sits at the 200-day moving average near $43, while resistance is at the $55 level, which has capped rallies three times since 2024. A breakout above $55 on high volume would signal institutional accumulation ahead of the data. A break below $43 would suggest a loss of confidence and a test of the $38 support zone.
A reiteration, especially with an unchanged price target, signals sustained analyst conviction despite recent stock price volatility. For Mirum, it indicates Citizens JMP has reviewed interim trial dynamics or management commentary and sees no reason to alter its positive thesis. This often provides a reference point for other institutional investors evaluating their own positions ahead of major catalysts.
Mirum's strategy is distinct in targeting multiple cholestatic pruritus indications with the same mechanism. Albireo's Bylvay is approved for PFIC and Alagille syndrome, creating direct competition. Mirum's potential advantage with Livmarli in PFIC rests on a different dosing profile and a potentially broader patient population in its Phase 3 trial design. The PSC program for Volixibat addresses a larger market with no approved therapies, offering greater upside but also higher development risk.
Across all hepatology, the probability of Phase 3 success from Phase 2 is approximately 52%, according to a 2023 Biostatistics review. For rare cholestatic diseases, the rate is slightly higher, near 60%, due to well-defined patient populations and clear efficacy endpoints like pruritus reduction. This historical context underscores the binary, high-stakes nature of Mirum's upcoming data readouts.
Mirum's stock hinges on two late-2026 clinical trials that will determine its commercial trajectory for the rest of the decade.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.